Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus

Glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as 2 new classes of antihyperglycemic agents that also reduce cardiovascular risk. The relative benefits in patients with and without established atherosclerotic cardiovascular dis...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation (New York, N.Y.) N.Y.), 2019-04, Vol.139 (17), p.2022-2031
Hauptverfasser:	Zelniker, Thomas A, Wiviott, Stephen D, Raz, Itamar, Im, KyungAh, Goodrich, Erica L, Furtado, Remo H M, Bonaca, Marc P, Mosenzon, Ofri, Kato, Eri T, Cahn, Avivit, Bhatt, Deepak L, Leiter, Lawrence A, McGuire, Darren K, Wilding, John P H, Sabatine, Marc S
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Atherosclerosis - prevention & control Cardiovascular Diseases - prevention & control Clinical Trials as Topic Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Cardiomyopathies - etiology Diabetic Cardiomyopathies - prevention & control Diabetic Nephropathies - etiology Diabetic Nephropathies - prevention & control Female Glucagon-Like Peptide Receptors - agonists Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Kidney Diseases - prevention & control Male Middle Aged Proportional Hazards Models Sodium-Glucose Transporter 2 Inhibitors - pharmacology Sodium-Glucose Transporter 2 Inhibitors - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!